<DOC>
	<DOCNO>NCT01562938</DOCNO>
	<brief_summary>This Phase 1 , double-blind , placebo control study enrol 42 healthy adult subject ( 18-45yrs ) 1 site . Subjects randomize 2:3:2 ratio receive MEDI-557 placebo . Subjects receive 1 intravenous dose Study Day 1 . Subjects follow safety time Informed Consent 360 day post dose .</brief_summary>
	<brief_title>MEDI-557 Adult Dosing</brief_title>
	<detailed_description>A Phase 1 , randomize , double-blind , placebo-controlled study evaluate safety tolerability MEDI-557 administer IV healthy adult subject ( 18-45yrs ) . A maximum 42 subject 1 site enrol 2:3:2 ratio ( 12 placebo , 18 MEDI-557 low-dose , 12 MEDI-557 high-dose ) allow great data collection low-dose group . Subjects evaluate safety time Informed Consent Study Day 360 post dose .</detailed_description>
	<criteria>1845 year write informed consent obtain subject prior perform protocol related procedure healthy medical history physical exam female childbearing potential must use 2 effective method birth control 14 day prior 1st dose 1 year administration study drug nonsterilized , sexually active male female partner childbearing potential must use 2 effective method birth control Day 1 Day 361 weight &lt; /= 110kg body mass index &lt; 32kg/m2 ability complete followup period approximately 360 day inability complete followup period 360 day condition opinion investigator would interfere evaluation IP interpretation subject safety study result concurrent enrollment another clinical study employee site individual involve conduct study immediate family member individual receipt immunoglobulin blood product within 60 day prior randomziation receipt investigational drug therapy within 6 month prior IP dose clinically abnormal ECG screen blood donation excess 400mL , wihtin 6 month prior randomization previous receipt fo biologics history immunodeficiency history allergic disease reaction likely exacerbate component IP previous medical history evidence interurrent illness may compromise safety subject positive lab test Hep A , B , C HIV pregnancy nurse mother history alcohol drug abuse within past 2 year positive urine Class A drug screen acute illness within 7 day prior randomization fever &gt; /= 99.5F witin 7 day prior randomization drug therapy within 7 day prior randomization systolic BP &gt; 150mmHG and/or diastolic BP &gt; 90mmHg receipt vaccine within 14 day prior randomization abnormal study lab ( hem/wbc/platelet/BUN see protocol specific information )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Respiratory Syncytial Virus</keyword>
</DOC>